In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.
The Food and Drug Administration has approved a new pancreatic cancer drug, a pill that nearly doubled patients average survival times for one of the deadliest cancers when taken instead of chemother… [+3 chars]
Discussion (0)
No comments yet. Be the first to share your thoughts!
Join the Conversation
You need to be logged in to leave a comment.
Sign In Create Account